¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cross over value"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carry-over effect
    ÀÜÈ¿
  • over refraction
    µ¡´ï±¼Àý°Ë»ç
  • biological value
    »ý¹°ÇÐÀû°¡Ä¡
  • group reference value
    Áý´ÜÂü°íÄ¡
  • half-value layer
    ¹Ý°¡Ãþ
  • individualized reference value
    °³º°ÀûÂü°íÄ¡
  • maximum allowable value
    ÃÖ´ëÇã¿ëÄ¡
  • normal value
    Á¤»óÄ¡, Á¤»ó°ª
  • positive predictive value
    ¾ç¼º¿¹ÃøÄ¡
  • predictive value
    ¿¹ÃøÄ¡
  • reference value
    ±âÁØÄ¡, ±âÁذª
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • value
    °ª, °¡Ä¡, Ä¡
  • value system
    °¡Ä¡Ã¼°è
  • blue cross
    û½ÊÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cross
    ±³Â÷
  • cross matching
    ±³Â÷½ÃÇè
  • cross reaction
    ±³Â÷¹ÝÀÀ
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • value
    °ª, °¡Ä¡, Ä¡
  • normal value
    Á¤»óÄ¡
  • positive predictive value
    ¾ç¼º¿¹ÃøÄ¡
  • predictive value
    ¿¹ÃøÄ¡
  • threshold value
    ¹®Åΰª, ¿ªÄ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nerve cross over
    ½Å°æ±³Â÷¼ú
  • carry-over effect
    ÀÜÈ¿
  • crossing-over suppressor
    ±³Â÷¾ïÁ¦ÀÎÀÚ
  • tie-over dressing
    ºÀÇÕ°íÁ¤µå·¹½Ì
  • over refraction
    µ¡´ï±¼Àý°Ë»ç
  • biological value
    »ý¹°ÇÐÀû°¡Ä¡
  • correction value
    º¸Á¤Ä¡
  • crossover value
    ±³Â÷°ª
  • effective value
    À¯È¿°ª
  • end dilution value
    ü¿ÜÈñ¼®Ä¡
  • group reference value
    Áý´Ü±âÁØÄ¡
  • half-value layer
    ¹Ý°¡Ãþ
  • individualized reference value
    °³º°ÀûÂü°íÄ¡
  • maximum allowable value
    ÃÖ´ëÇã¿ëÄ¡
  • molar buffer value
    ¸ô¿ÏÃæ°¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • OTC drug : over-the-counter drug
    ÀϹݸžà.
  • Cross bridge
    ±³Â÷°áÇÕ(Îßó©Ì¿ùê), ¿¬°á±³
  • Cross bridge cycle
    ±³Â÷°áÇÕÁÖ±â(Îßó©Ì¿ùêñÎÑ¢)
  • Cross-Bevan reagent
    Å©·Î½º-º£¹Ý½Ã¾à.
  • Jackson cross cylinder
    Àè½¼±³Â÷¿øÁÖ(·»Áî)
  • absorption, cross
    ±³Â÷Èí¼ö½ÃÇè
  • antibody, cross-reacting
    ±³Â÷¹ÝÀÀÇ×ü
  • antigen, cross-reacting
    ±³Â÷¹ÝÀÀÇ׿ø
  • genus cross
    ¼Ó°£±³¹è(áÕÊàÎßÛÕ).
  • immunity, cross
    ±³Â÷¸é¿ª
  • incision, cross hatching
    ±³Â÷Àý°³(¼ú)
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè(úìíìÎßó©ãËúÐ).
  • Q value
    Q °ª
  • acid value
    »ê°ª, »ê°¡(߫ʤ).
  • gamma value
    °¨¸¶Ä¡
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cross over value
    ±³Â÷°ª.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cross-over
    ±³¹è(ÎßÛÕ), ±³Â÷(Îßó©).
  • bed turn over rate
    º´»óȸÀüÀ²
  • carry-over
    ÀÜÈ¿(íÑüù)
  • carry-over effect
    ÀÜÈ¿(íÑüù).
  • crossing over
    À¯ÀüÀÚ±³È¯(ë¶îîí­Îßüµ), ±³Â÷.
  • crossing over
    À¯ÀüÀÚ±³È¯
  • crossing over
    ±³Â÷, ±³¹è.
  • crossing over suppressor
    ±³Â÷¾ï¾ÐÀÎÀÚ(¡­åääâì×í­).
  • draw-over vaporizer
    ¼ÒÀÎ(½Ä)±âÈ­±â.
  • over correction
    °ú±³Á¤
  • over refraction
    µ¡´ï±¼Àý°Ë»ç
  • sum over state
    »óÅÂÈ­(ßÒ÷¾ûú).
  • sum over state
    »óÅÂÈ­(Ë×̴̬).
  • tie over dressing
    ºÀÇպشë.
  • acid value
    »ê°ª, »ê°¡(߫ʤ).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cross copulation
    ±³Â÷±³¹Ì
  • cross fertilization
    ±³Â÷¼öÁ¤
  • cross protection
    ±³Â÷¹æ¾î
  • cross resistance
    ±³Â÷ÀúÇ×
  • maltese cross
    ¸ôŸ½ÊÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • crossing over
    "±³Â÷(Îßó©), ±³¹è(ÎßÛÕ)"
  • somatic crossing over
    ü¼¼Æ÷ ±³Â÷(ô÷á¬øàÎßó©)
  • biological value
    »ý¹°°¡(ßæÚªÊ¤)
  • buffer value
    ¿ÏÃæ(èÐõú)°ª
  • caloric value
    Ä®·Î¸® °ª
  • Cot value
    Cot Ä¡(ö·)
  • C value
    C °ª
  • C value paradox
    C °ª ÆÄ¶óµ¶½º
  • dilution value of buffer
    ¿ÏÃæ¾× Èñ¼®°¡(èÐõúäûýüà·Ê¤)
  • D value
    D °ª (ÔÒ) decimal reduction time
  • ester value
    ¿¡½ºÅÍ °ª
  • F value
    F °ª
  • g value
    g °ª
  • G value
    G °ª
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • over extension
    °úµµ¿¬Àå, °ú´Ù½ÅÀü
  • over-estimate
    °ú´ëÃßÁ¤
  • gamma value
    °¨¸¶Ä¡
  • normal value
    Á¤»óÄ¡, Ç¥ÁØÄ¡, ±ÔÁ¤Ä¡
  • positive predictive value [=PPV]
    ¾ç¼º¿¹ÃøÄ¡
  • postive predictive value
    ¾ç¼º¿¹ÃøÄ¡
  • Q value
    Q °ª
  • value
    °ª, °¡Ä¡
  • cross
    ±³Â÷, ±³¹è, ±³Àâ
  • cross link
    ±³Â÷°áÇÕ, Ⱦ°áÇÕ
  • cross matching
    ±³Â÷ÀûÇÕ½ÃÇè¹ý
  • cross relaxation
    ±³Â÷ ÀÌ¿Ï
  • cross section radiography
    ´ÜÃþÃÔ¿µ¼ú
  • cross sectional echocardiography
    ´ÜÃþ½ÉÃÊÀ½ÆÄ°Ë»ç
  • cross talk
    ±³Â÷´ëÈ­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
COV covariance; cross-over value
NPV negative predictive value; pressure value; negative pressure ventilation; net present value; nuclear...
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
CO carbon monoxide; cardiac output; castor oil; casualty officer; centric occlusion; cervical orthosis;...
OD   1) Doctor of Optometry
  2) Oculus Dexter; Right Eye; ¿ìÃø´«
  3)...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
EOI Emotional Over-Involvement
NOESY Nuclear Over-hauser enhancement spectroscopy
OTC Over The Counter
ROPS Roll-over protective structures
ROT Roll-over test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cross-over position
    ¹Ý´ëÀ§
  • change over time
    ½Ã°£¿¡ µû¸¥ º¯È­
  • constant turn over
    ÀÏÁ¤ÇÑ È¸Àü
  • crossing over
    ±³¹è, ±³Â÷
    Á¦ 1°¨¼öºÐ¿­ÀÇ Å»ç±â Áß¿¡ ½ÖÀ» ÀÌ·ç´Â »óµ¿ ¿°»öüÀÇ ºñÀڸŠ¿°»öºÐü »çÀÌ¿¡¼­ ÀϾ´Â À¯Àü¹°ÀÇ ±³È¯. ±× °á°ú·Î »õ·Î¿î À¯ÀüÀÚÀÇ Á¶ÇÕÀÌ ÀϾ´Ù.
  • over carve
    °úÀ× Á¶°¢
  • over interpretation
    °ú´Ù ÆÇµ¶
  • over work
    °ú·Î
  • slide over
    -À» ó¸®ÇÏ´Ù
  • absolute value
    Àý´ë °ª, Àý´ë Ä¡
    ½Ç¼ö¿¡¼­ ¾ç ¶Ç´Â À½ÀÇ ºÎÈ£¸¦ ¶¼¾î¹ö¸° ¼ö.
  • acid value
    »ê°ª, »ê°¡
    À¯Áö 1g¿¡ ÇÔÀ¯µÈ À¯¸® Áö¹æ»êÀ» ÁßÈ­Çϴµ¥ ÇÊ¿äÇÑ ¼ö»êÈ­Ä®·ýÀÇ §·¼ö¸¦ »ê°¡¶ó ÇÑ´Ù. À¯Áö´Â ¿À·¡ µÇ¸é À¯¸® Áö¹æ»êÀÌ Áõ°¡ÇϹǷΠ½Å¼±µµ µîÀÇ ±âÁØÀÌ µÈ´Ù. ½Ä¿ëÀ¯Áö´Â »ê°¡ 1 ÀÌÇÏÀÇ °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù°í ÇÑ´Ù.
  • average value
    Æò±ÕÄ¡
  • boundary value
    °æ°èÄ¡
  • correction value
    º¸Á¤Ä¡
  • fasting value
    °øº¹Ä¡
  • mean value
    Æò±ÕÄ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
aged, 80 and over A person 80 years of age and older.
(12 Dec 1998)
maternal age 35 and over Pregnancy in women 35 or more years of age. It is used for normal pregnancies and for problems of pregnancy occurring in a woman's late reproductive years. These include effects on the mother's physical and mental health as well as risks of perinatal mortality and foetal abnormality.
(12 Dec 1998)
crossing over <genetics, molecular biology> The breaking during meiosis of one maternal and one paternal chromosome, the reciprocal exchange of corresponding sections of DNA along pairs of homologous chromosomes by symmetrical breakage and crosswise rejoining of the chromosomes.
This results in the transfer of a block of genes from each chromosome to its homologue. In contrast to genetic recombination, which is a phenotypic phenomenon, crossing-over is genotypic. Any even number of crossing-overs between two loci will cancel out phenotypically and no recombination will occur.
Recombination can result from DNA exchange of alleles between between homologous chromatids in meiosis, giving rise to chiasmata.
Compare: recombination.
(10 Nov 1998)
somatic crossing-over Crossing-over that occurs during the mitosis of somatic cells, in contrast to that which occurs in meiosis.
(05 Mar 2000)
drug, over-the-counter Drug for which a prescription is not needed.
(12 Dec 1998)
tie-over dressing A dressing placed over a skin graft or other sutured wound and tied on by the sutures which have been left of sufficient length for that purpose.
Synonym: bolus dressing.
(05 Mar 2000)
unequal crossing over <cell biology> Crossing over between homologous chromosomes that are not precisely paired, resulting in nonreciprocal exchange of material and chromosomes of unequal length. Favoured in regions containing tandemly repeated sequences.
(18 Nov 1997)
uneven crossing-over Unequal crossing-over, crossing-over that happens when the breaks do not occur at precisely homologous points in two chromatid strands, and hence results in localised duplication of genetic material in one chromatid and complementary deletion in the other.
(05 Mar 2000)
flip-over disease <disease> A disease of young, fast-growing broiler chickens which causes them to die suddenly with a short, terminal, wing-beating convulsion, whereby they often flip over and die on their backs.
(05 Mar 2000)
flow-over vaporiser A device for vaporization of a liquid anaesthetic by causing gases to pass over the anaesthetic or over material saturated with the anaesthetic.
(05 Mar 2000)
four-strand crossing over Crossing over with both strands of DNA from each sister chromatid, so that both strands from one chromatid are exchanged for both strands on the other. This is different from the usual case where only one of the two DNA strands on one sister chromatid is exchanged for the one matching strand (of the two strands) on the other sister chromatid.
(09 Oct 1997)
acetyl value The milligrams of KOH required to neutralise the acetic acid produced by the hydrolysis of 1 g of acetylated fat; a measure of the hydroxy acids present in glycerides; notably high in castor oil.
(05 Mar 2000)
beta, or beta-value <radiobiology> Ratio of plasma kinetic pressure to magnetic-field pressure, proportional to the ratio of plasma kinetic energy density to magnetic field energy density. Beta is usually measured relative to the total, local field (loosely called beta toroidal), but sometimes the plasma pressure relative to only the poloidal component of the field (beta poloidal) or relative to some external field (like the maximum field at the magnetic coils) is more useful. There is also a normalised beta (beta_N) of interest when discussing the beta limit. (lots of help from Art Carlson with the above.) Because the cost of a reactor is strongly influenced by the strength of the magnetic field that must be provided, beta values are directly related to the economics of fusion power production. Beta is usually expressed as a percentage, with 5% generally believed to be the minimum value required for an economical fusion reactor.
See: pressure, kinetic pressure, magnetic pressure, second stability.
(09 Oct 1997)
biological value <nutrition> The nutritional value of a protein, usually measured in comparison to the nutritional value of egg protein, which is the highest possible (BV=0.9 - 1.00).
(21 Mar 1998)
buffer value The power of a substance in solution to absorb acid or alkali without change in pH; this is highest at a pH value equal to the pKa value of the acid of the buffer pair.
See: buffer capacity.
Synonym: buffer index.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • over and over again
    µÇÇ®ÀÌÇØ¼­
  • scarcity value
    Èñ¼Ò °¡Ä¡.
  • value
    °¡Ä¡,Æò°¡ÇÏ´Ù
  • R-value
    (resistance value)°ÇÃàÀç·áµîÀÇ ´Ü¿­¼º´ÉÄ¡
  • absolute value
    Àý´ë°ª
  • atomic value
    ¿øÀÚ°¡
  • atonic value
    ¿øÀÚ°¡
  • book value
    ÀåºÎ°¡°Ý
  • calorific value
    ¹ß¿­·®
  • cash (surrender) value
    ÇØ¾à ¹Ýȯ±Ý(º¸Çè °è¾à ÇØ¾à½Ã ¹ÝȯµÇ´Â ±Ý¾×)
  • exchange value
    (°æ)±³È¯ °¡Ä¡
  • expected value
    (Åë°è)±â´ë°ª
  • face value
    ¾×¸é °¡°Ý;±Ç¸é¾×;¾×¸é(Ç¥¸é)»óÀÇ °¡Ä¡(ÀǹÌ)
  • food value
    (½ÄǰÀÇ) ¿µ¾ç°¡
  • market value
    ½ÃÀå °¡°Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á